Daniel Semenza was reviewing behavioral data from across the U.S. when a pattern emerged so striking it gave him pause: among people taking GLP-1 medications like Ozempic and Wegovy, the usual path from impulsive thought to violent action seemed to short-circuit. At the New Jersey Gun Violence Research Center at Rutgers University, Semenza and his team uncovered a surprising ripple effect of these widely used drugs—one that extends far beyond weight loss and diabetes management. Their study, published in Criminology and based on a 2025 national survey of 7,521 adults, suggests that GLP-1 receptor agonists may be quietly reshaping one of society’s most persistent challenges: violent behavior.
Violence is often fueled by two well-documented accelerants: impulsivity and alcohol. But in this analysis of 821 GLP-1 users, those accelerants lost much of their power. For current users, the link between impulsivity and violent acts—such as fighting, assault, or robbery—was 62% weaker than among former users. Even the connection between alcohol use and violence weakened by about 52%, though this result varied across follow-up tests. These findings don’t mean the drugs erase risky behavior, but they do suggest a profound dampening effect on the impulse-to-action pathway.
"The strongest finding in the study was that the well-established link between impulsivity and violent behavior was substantially weaker among current GLP-1 users compared to former users," said Semenza, who is also an associate professor at the Rutgers School of Public Health. Coauthor Christopher Thomas, an assistant professor at Rutgers University-Camden, likened the effect to cognitive behavioral therapy: not eliminating the impulse, but creating a mental pause before action. This distinction is crucial—it suggests the medication may help people interrupt automatic, aggressive responses.
The implications could be far-reaching. With over 8 million Americans now using GLP-1 drugs and prescriptions rising steadily, even a modest reduction in impulsive violence could translate into meaningful public safety benefits. The study’s self-reported measures of violent behavior add nuance, capturing real-world actions rather than theoretical risk. Still, the researchers emphasize caution: because the data are observational and cross-sectional, they can’t prove cause and effect. It’s possible other factors—lifestyle changes, improved mental health, or socioeconomic variables—play a role.
What’s clear is that this is only the beginning. As GLP-1 medications become embedded in American healthcare, their side effects—both intended and unexpected—demand closer scrutiny. Longitudinal and experimental studies are now needed to confirm whether these drugs can reliably disrupt the chain of violence. If so, a medication designed for metabolism may end up influencing not just waistlines, but the way we manage conflict, control impulses, and build safer communities.